A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Research output: Contribution to journalArticle

Abstract

This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Hodgkin lymphoma
  • Multiple myeloma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies'. Together they form a unique fingerprint.

  • Cite this